Douglas Johnson Archive
-
August 10, 2023
New leaders named to Vanderbilt-Ingram research programs
Seven new leaders have been appointed to guide Vanderbilt-Ingram Cancer Center’s research programs. -
August 8, 2023
Chronic complications from immunotherapies more prevalent and persistent than previously shown among melanoma survivors
A Vanderbilt study has found that chronic immunotherapy-related complications are more prevalent and persistent than previously shown among melanoma survivors. -
November 17, 2022
Several from VUMC among most highly cited researchers
Nine current faculty members of the Vanderbilt University School of Medicine have made this year’s list of scientists whose papers have been cited most frequently by other researchers. -
August 18, 2022
Abramson, Eng, Johnson named to new VICC roles
Three physician researchers at Vanderbilt-Ingram Cancer Center are assuming additional leadership roles. -
November 18, 2021
Seven from VUMC among most highly cited researchers
Seven Vanderbilt faculty members have made this year’s list of scientists whose papers have been cited most frequently by other researchers. -
April 18, 2019
Medical Societies honor multiple Vanderbilt faculty
Several Vanderbilt faculty members were recently honored during the joint annual meeting of the Association of American Physicians (AAP) and American Society for Clinical Investigation (ASCI). -
October 29, 2015
Investigators find clues to melanoma treatment resistance
Nearly half of all patients with malignant melanoma, the most deadly form of skin cancer, have a mutation in the BRAF gene found in their tumors. Mutations in the BRAF gene turn on a cancer growth switch known as the MAP kinase pathway.